[go: up one dir, main page]

SE0303075D0 - 4-substituted imidazoles - Google Patents

4-substituted imidazoles

Info

Publication number
SE0303075D0
SE0303075D0 SE0303075A SE0303075A SE0303075D0 SE 0303075 D0 SE0303075 D0 SE 0303075D0 SE 0303075 A SE0303075 A SE 0303075A SE 0303075 A SE0303075 A SE 0303075A SE 0303075 D0 SE0303075 D0 SE 0303075D0
Authority
SE
Sweden
Prior art keywords
substituted imidazoles
sup
psychotic
prophylaxis
therapy
Prior art date
Application number
SE0303075A
Other languages
English (en)
Inventor
Eifion Phillips
James Empfield
Scott Throner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0303075A priority Critical patent/SE0303075D0/sv
Publication of SE0303075D0 publication Critical patent/SE0303075D0/sv
Priority to EP04800323A priority patent/EP1687303A1/en
Priority to US10/579,609 priority patent/US7384954B2/en
Priority to PCT/SE2004/001660 priority patent/WO2005049612A1/en
Priority to KR1020067009700A priority patent/KR20060100426A/ko
Priority to BRPI0416629-9A priority patent/BRPI0416629A/pt
Priority to CA002546096A priority patent/CA2546096A1/en
Priority to AU2004291457A priority patent/AU2004291457A1/en
Priority to JP2006541086A priority patent/JP2007511603A/ja
Priority to CNA2004800342450A priority patent/CN1882584A/zh
Priority to IL175438A priority patent/IL175438A0/en
Priority to ZA200604018A priority patent/ZA200604018B/en
Priority to NO20062862A priority patent/NO20062862L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0303075A 2003-11-19 2003-11-19 4-substituted imidazoles SE0303075D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0303075A SE0303075D0 (sv) 2003-11-19 2003-11-19 4-substituted imidazoles
CNA2004800342450A CN1882584A (zh) 2003-11-19 2004-11-15 4－取代的咪唑
KR1020067009700A KR20060100426A (ko) 2003-11-19 2004-11-15 4-치환된 이미다졸
US10/579,609 US7384954B2 (en) 2003-11-19 2004-11-15 4-substituted imidazoles
PCT/SE2004/001660 WO2005049612A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles
EP04800323A EP1687303A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles
BRPI0416629-9A BRPI0416629A (pt) 2003-11-19 2004-11-15 composto, métodos de tratamento ou de profilaxia de uma doença ou condição, de distúrbios, composição farmacêutica, método de indução da cessação de fumar, e, uso de um composto
CA002546096A CA2546096A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles
AU2004291457A AU2004291457A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles
JP2006541086A JP2007511603A (ja) 2003-11-19 2004-11-15 ４−置換イミダゾール類
IL175438A IL175438A0 (en) 2003-11-19 2006-05-04 4-substituted imidazoles
ZA200604018A ZA200604018B (en) 2003-11-19 2006-05-18 4-Substituted imidazoles
NO20062862A NO20062862L (no) 2003-11-19 2006-06-19 4-substituerte imidazoler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303075A SE0303075D0 (sv) 2003-11-19 2003-11-19 4-substituted imidazoles

Publications (1)

Publication Number Publication Date
SE0303075D0 true SE0303075D0 (sv) 2003-11-19

Family

ID=29729099

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0303075A SE0303075D0 (sv) 2003-11-19 2003-11-19 4-substituted imidazoles

Country Status (13)

Country Link
US (1) US7384954B2 (sv)
EP (1) EP1687303A1 (sv)
JP (1) JP2007511603A (sv)
KR (1) KR20060100426A (sv)
CN (1) CN1882584A (sv)
AU (1) AU2004291457A1 (sv)
BR (1) BRPI0416629A (sv)
CA (1) CA2546096A1 (sv)
IL (1) IL175438A0 (sv)
NO (1) NO20062862L (sv)
SE (1) SE0303075D0 (sv)
WO (1) WO2005049612A1 (sv)
ZA (1) ZA200604018B (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
AU2005317235A1 (en) * 2004-12-16 2006-06-22 Astrazeneca Ab Nicotinic acetycholine receptor ligands
FR2974365B1 (fr) * 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
EP1562945B1 (en) 2002-11-11 2006-11-15 Neurosearch A/S 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof

Also Published As

Publication number Publication date
AU2004291457A1 (en) 2005-06-02
JP2007511603A (ja) 2007-05-10
WO2005049612A1 (en) 2005-06-02
EP1687303A1 (en) 2006-08-09
CN1882584A (zh) 2006-12-20
US7384954B2 (en) 2008-06-10
NO20062862L (no) 2006-08-21
CA2546096A1 (en) 2005-06-02
BRPI0416629A (pt) 2007-01-16
US20070105896A1 (en) 2007-05-10
KR20060100426A (ko) 2006-09-20
IL175438A0 (en) 2006-09-05
ZA200604018B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
ATE248837T1 (de) Chinuclidin-acrylamide
SE9904176D0 (sv) New use
SE0401971D0 (sv) Piperidne derivatives
TW200500358A (en) Compounds
SE0200920D0 (sv) Novel compounds
SE0202463D0 (sv) Novel compounds
DE602004024375D1 (de) Carboxamidderivate
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
SE0300480D0 (sv) Novel compounds
GB0112348D0 (en) Compounds
TW200613243A (en) Novel compounds
ATE384058T1 (de) Thiazolderivate
SE0401970D0 (sv) Novel compounds
MXPA05012247A (es) Derivados de bencimidazol nuevos.
SE0302139D0 (sv) Novel compounds
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
SE0302756D0 (sv) Novel Compounds
TW200639156A (en) New compounds
SE0401763D0 (sv) Compounds
SE0303280D0 (sv) Novel compounds
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
SE0202693D0 (sv) Compounds
SE0302755D0 (sv) Novel compounds